Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells

Molecular Therapy

Volumn 16, Issue 10, 2008, Pages 1753-1760

  Akbulut, Hakan ^a   Tang, Yucheng ^b   Akbulut, Gonca K ^c   Maynard, Jonathan ^b   Deisseroth, Albert ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; FLUCYTOSINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL STRAIN HEK293; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SOLID TUMOR; SURVIVAL TIME; TUMOR CELL DESTRUCTION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CANCER VACCINES; DENDRITIC CELLS; DNA PRIMERS; FLUCYTOSINE; FLUOROURACIL; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; MICE; NEOPLASMS, EXPERIMENTAL;

MUS;

EID: 54849391800     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.158     Document Type: Article

References (25)

1. Fanslow, WC, Srinivasan, S, Paxton, R, Gibson, MG, Spriggs, MK and Armitage, RJ (1994). Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 6: 267-278.
2. Wurtzen, PA, Nissen, MH and Claesson, MH (2001). Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol 53: 579-587.
3. Akbulut, H, Tang, Y, Maynard, J, Zhang, L, Pizzorno, G and Deisseroth, A (2004). Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res 10: 7738-7746.
4. Zhang, L, Tang, Y, Akbulut, H, Zelterman, D, Linton, PJ and Deisseroth, A (2003). An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 100: 15101-15106.
5. Tang, Y, Zhang, L, Yuan, J, Akbulut, H, Maynard, J, Linton, PJ et al. (2004). Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. Blood 104: 2704-2713.
6. Tang, Y, Akbulut, H, Maynard, J, Petersen, L, Fang, X, Zhang, WW et al. (2006). Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J Immunol 177: 5697-56707.
7. Eaton, SM, Burns, EM, Kusser, K, Randall, TD and Haynes, L (2004). Age-related defects in CD4 cell cognate helper function lead to reductions in humoral responses. J Exp Med 200: 1613-1622.
8. Dong, L, More, I, Hossain, MJ, Liu, B and Kimura, Y (2003). An immunostimulatory oligodeoxynucleotide containing a cytodine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J Gen Virol 84: 1623-1628.
9. Tan, PH, Beutelspacher, SC, Xue, SA, Wang, YH, Mitchell, P, McAlister, JC et al. (2005). Modulation of human dendritic cell function following transduction with viral vectors: Implications for gene therapy. Blood 105: 3824-3832.
10. Matzinger, P (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
11. Banchereau, J, Briere, F, Caux, C, Davoust, J, Lebecque, S, Liu, Y et al. (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
12. Shi, Y, Zheng, W and Rock, KL (2000). Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 97: 14590-14595.
13. Akbulut, H, Zhang, L, Tang, Y and Deisseroth, A (2003). The cytotoxic effect of replication competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther 10: 388-395.
14. Peng, XY, Won, JH, Rutherford, T, Fujii, T, Zelterman, D, Pizzorno, G et al. (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res 61: 4405-4413.
15. Kievit, E, Nyrati, MK, Ng, E, Stegman, LD, Parsels, J, Ross, BD et al. (2000). Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-Fluorocytosine of human colorectal cancer xenografts. Cancer Res 60: 6649-6655.
16. Block, A, Freund, CT, Chen, SH, Nguyen, KP, Finegold, M, Windier, E et al. (2000). Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase. Cancer Gene Ther 7: 438-445.
17. Ichikawa, T, Tamiya, T, Adachi, Y, Ono, Y, Matsumoto, K, Furuta, T et al. (2000). In vivo efficacy and toxicity of 5-fluorocytosine/ cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 7: 74-82.
18. Alkbulut, H, Tang, Y, Akbulut, KG, Maynard, J, Zhang, L and Deisseroth, A (2006). Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 5: 1975-1985.
19. Jamicki, AG, Lysaght, J, Todryk, S and Mills, KH (2006). Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177: 896-904.
20. Strauss, L, Bergmann, C, Gooding, W, Johnson, JT and Whiteside, TL (2007). The frequency and suppressor function of CD4+CD25highFoxP3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 6301-6311.
21. Liu, VC, Wong, LY, Jang, T, Shah, AH, Park, J, Yang, X et al. (2007). Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: Role of tumor-derived TGF-beta. J Immunol 178: 2883-2892.
22. He, TZ, Zhou, S, da Costa, LT, Yu, J, Kinzler, KW and Vogelstein, BA (1998). Symplified system for generating recombinant adenovirus. Proc Natl Acad Sci USA 95: 2509-2514.
23. Becker, TC, Noel, RJ, Coats, WS, Gómez-Foix, AM, Alam, T, Gerard, RD et al. (1994). Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43: 161-189.
24. Clay, TM, Hobeika, AC, Mosca, PJ, Lyerly, HK and Morse, MA (2001). Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7: 1127-1135.
25. Rininsland, FH, Helms, T, Asaad, RJ, Boehm, BO and Tary-Lehmann, M (2000). Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240: 143-155.